Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
Open Access
- 29 July 2011
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 126
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) still remains a lethal malignancy benefiting from the identification of the new target for early detection and/or development of new therapeutic regimens based on a better understanding of the biological mechanism for treatment. The overexpression of Her2 and Her3 receptors have been identified in various solid tumors, but its prognostic relevance in HNSCC remains controversial. Methods: Three hundred eighty-seven primary HNSCCs, 20 matching metasis and 17 recurrent HNSCCs were arrayed into tissue microarrays. The relationships between Her2 and Her3 protein expression and clinicopathological parameters/survival of HNSCC patients were analyzed with immunohistochemistry. Results: Her3 is detected as either a cytoplasmic or a membranous dominant expression pattern whereas Her2 expression showed uniform membranous form. In primary tumor tissues, high membranous Her2 expression level was found in 104 (26.9%) cases while positive membranous and cytoplasmic Her3 expression was observed in 34 (8.8%) and 300 (77.5%) samples, respectively. Membranous Her2 expression was significantly associated with histological grade (P = 0.021), as grade 2 tumors showed the highest positive expression. Membranous Her3 over-expression was significantly prevalent in metastatic tissues compared to primary tumors (P = 0.003). Survival analysis indicates that membranous Her3 expression is significantly associated with worse overall survival (P = 0.027) and is an independent prognostic factor in multivariate analysis (hazard ratio, 1.51; 95% confidence interval, 1.01-2.23; P = 0.040). Conclusions: These results suggest that membranous Her3 expression is strongly associated with poor prognosis of patients with HNSCC and is a potential candidate molecule for targeted therapy.Keywords
This publication has 46 references indexed in Scilit:
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- High Expression of HER3 Is Associated with a Decreased Survival in Gastric CancerClinical Cancer Research, 2008
- Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patientsBreast Cancer Research, 2008
- The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literatureDiagnostic Cytopathology, 2007
- PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomasBritish Journal of Cancer, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998